Recipharm divests two manufacturing sites

China’s Pharmaron Beijing (3759: HK) has acquired Aesica Pharmaceuticals (the Cramlington Site) from Swedish Contract Development and Manufacturing Organization (CDMO) Recipharm group.

The Cramlington Site in Newcastle, UK, has an established history of cGMP manufacturing services for an array of Active Pharmaceutical Ingredients (API), ranging from pilot scale to commercial metric ton scale. This adds to Pharmaron’s acquisition of Allergan Biologics Limited (ABL) in Liverpool, UK, from AbbVie (NYSE: ABBV) for $118.7 million in cash last year.

This acquisition expands Pharmaron's world-class chemistry and manufacturing services, which is an important component of its fully integrated platform. The synergistic integration of the Cramlington Site with Pharmaron’s existing service capabilities of discovery, process development and early-stage cGMP API manufacturing at Hoddesdon will enable a complete end-to-end chemistry and manufacturing service offering in the UK.